Posted by Michael Wonder on 14 Dec 2024
Galderma receives US FDA approval for Nemluvio (nemolizumab) for patients with moderate to severe atopic dermatitis
13 December 2024 - Galderma today announced that the US FDA has approved Nemluvio (nemolizumab) for the treatment of patients 12 years and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
This follows the recent US FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.
